DragonCure

DragonCure is a biotech startup developing an innovative anti-cancer nutraceutical targeting chemo-resistant cancer stem cells (CSCs) in triple-negative breast cancer. By combining natural Hylocereus undatus (dragon fruit) extracts with verapamil, our formulation inhibits the ABCB1 efflux pump, enhancing chemotherapy effectiveness. DragonCure aims to offer a natural, cost-effective, and scientifically validated adjunct therapy to improve patient outcomes and reduce resistance to conventional cancer treatments.

Contact: Samashi Munaweera, samashi.munaweera@gmail.com